Key Events This Week
25 May: Stock dips 0.92% amid broad market rally
26 May: Intraday high of Rs.404 with a 10.69% surge
27 May: Strong quarterly results announced, stock rises 5.91%
29 May: Profit-taking leads to 5.60% decline, week closes at Rs.403.60

FDC Ltd Reports Strong Quarterly Turnaround Amid Positive Financial Trend
2026-05-29 08:00:12FDC Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable financial turnaround in the quarter ended March 2026. After a period of negative trends, the company’s recent quarterly results reveal significant growth in profitability metrics, signalling a positive shift in its financial trajectory despite lingering concerns over non-operating income contributions.
Read full news articleAre FDC Ltd latest results good or bad?
2026-05-28 19:21:46FDC Ltd's latest financial results for Q4 FY26 present a complex picture. The company reported a net profit of ₹103.40 crore, reflecting a significant year-on-year growth of 167.39%. Revenue for the same quarter reached ₹584.79 crore, marking an 18.89% increase compared to the previous year. The operating margin improved to 18.19%, up from 10.97% in Q4 FY25, indicating a positive trend in operational efficiency. However, the results also reveal underlying concerns. A notable portion of the profit, ₹49.89 crore, came from other income, which constituted 35.55% of profit before tax, raising questions about the sustainability of core business profitability. The reliance on non-operating income suggests potential vulnerabilities in the company's operational performance. The quarterly performance exhibited significant volatility, with revenue growth of 25.84% sequentially from the previous quarter, contrasting...
Read full news article
FDC Q4 FY26: Stellar Quarter Masks Underlying Profitability Concerns
2026-05-27 22:30:33FDC Ltd., a fully integrated pharmaceutical company specialising in formulations and active pharmaceutical ingredients, reported a remarkable turnaround in Q4 FY26 with consolidated net profit surging 167.39% year-on-year to ₹103.40 crores, compared to ₹38.67 crores in Q4 FY25. The quarter-on-quarter performance was even more dramatic, with profits jumping 265.37% from ₹28.30 crores in Q3 FY26. Despite this impressive headline performance, the stock has struggled over the past year, declining 6.95%, whilst the broader pharmaceuticals sector gained 11.45%. The company, with a market capitalisation of ₹6,692 crores, trades at a P/E multiple of 30x, reflecting investor concerns about sustainability of earnings and margin volatility.
Read full news article
FDC Ltd Surges 10.7% to Day's High of Rs 404 — Outperforms Sector by 8.7 Percentage Points
2026-05-26 13:01:17The Sensex declined 0.25% on 26 May 2026, while FDC Ltd surged 10.69%, marking a striking 8.66-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector. This sharp single-session gain rewrites the short-term narrative for the small-cap stock, which touched an intraday high of Rs 404, up 9.2% from its previous close.
Read full news article
FDC Ltd is Rated Strong Sell
2026-05-23 10:10:18FDC Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 06 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 May 2026, providing investors with the latest insights into its performance and outlook.
Read full news article








